$13.26
0.41 (+3.19%)
Elan Corp, plc (ADR) (NYSE:ELN)
CAPS Rating:
The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.
RSS Headlines
Fool UK
Recs
The stock was a little overpriced, but a 40% drop on OK news from its phase 2 trial for bapineuzumab puts it right back in the 'reasonably valued' class, and although the chances of gigantic success from bap have taken a baby step backwards, there is stille lots to look forward to, including natalizumab and its brilliant trajectory so far, and its safety profile which keep looking better with every passing month.